Diffuse Large B Cell Lymphoma: From Gene Expression Profiling to Prediction of Outcome

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Diffuse large B cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL), characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Recent studies have focused on the use of genome-scale expression profiles that provide a snap fingerprint of the tumor and identifying tumors with similar genetic alterations and clinical features. Gene expression studies have the ability to recognize distinct subgroups of patients based on similar molecular characteristics and markedly different outcomes that were independent of the International Prognostic Index (IPI). Further, DNA microarray studies also allow identification of new prognostic biomarkers in DLBCL. However, new methods for immunohistochemical analysis of tissue microarray and RNA extraction from paraffin-embedded blocks are required to overcome the major pitfall of this technology-the requirement for fresh tissue. Herein, we summarize the progress made in better prediction of prognosis of DLBCL patients as a result of gene expression profiling.

Original languageEnglish
Pages (from-to)108-111
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number1 SUPPL.
DOIs
StatePublished - Jan 1 2008

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Gene Expression Profiling
Tissue Array Analysis
Dermatoglyphics
Oligonucleotide Array Sequence Analysis
Paraffin
Non-Hodgkin's Lymphoma
Neoplasms
Biomarkers
Genome
RNA
Technology
Gene Expression
Therapeutics

Keywords

  • DLBCL
  • gene arrays
  • Prognostic biomarkers

ASJC Scopus subject areas

  • Transplantation

Cite this

Diffuse Large B Cell Lymphoma : From Gene Expression Profiling to Prediction of Outcome. / Lossos, Izidore.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 1 SUPPL., 01.01.2008, p. 108-111.

Research output: Contribution to journalArticle

@article{f131e2afe74a454b9087397fadb5d0cd,
title = "Diffuse Large B Cell Lymphoma: From Gene Expression Profiling to Prediction of Outcome",
abstract = "Diffuse large B cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL), characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Recent studies have focused on the use of genome-scale expression profiles that provide a snap fingerprint of the tumor and identifying tumors with similar genetic alterations and clinical features. Gene expression studies have the ability to recognize distinct subgroups of patients based on similar molecular characteristics and markedly different outcomes that were independent of the International Prognostic Index (IPI). Further, DNA microarray studies also allow identification of new prognostic biomarkers in DLBCL. However, new methods for immunohistochemical analysis of tissue microarray and RNA extraction from paraffin-embedded blocks are required to overcome the major pitfall of this technology-the requirement for fresh tissue. Herein, we summarize the progress made in better prediction of prognosis of DLBCL patients as a result of gene expression profiling.",
keywords = "DLBCL, gene arrays, Prognostic biomarkers",
author = "Izidore Lossos",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2007.10.020",
language = "English",
volume = "14",
pages = "108--111",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Diffuse Large B Cell Lymphoma

T2 - From Gene Expression Profiling to Prediction of Outcome

AU - Lossos, Izidore

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Diffuse large B cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL), characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Recent studies have focused on the use of genome-scale expression profiles that provide a snap fingerprint of the tumor and identifying tumors with similar genetic alterations and clinical features. Gene expression studies have the ability to recognize distinct subgroups of patients based on similar molecular characteristics and markedly different outcomes that were independent of the International Prognostic Index (IPI). Further, DNA microarray studies also allow identification of new prognostic biomarkers in DLBCL. However, new methods for immunohistochemical analysis of tissue microarray and RNA extraction from paraffin-embedded blocks are required to overcome the major pitfall of this technology-the requirement for fresh tissue. Herein, we summarize the progress made in better prediction of prognosis of DLBCL patients as a result of gene expression profiling.

AB - Diffuse large B cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL), characterized by a markedly heterogeneous clinical course and response to therapy that is not appreciated with standard histopathologic and immunophenotypic evaluations. Recent studies have focused on the use of genome-scale expression profiles that provide a snap fingerprint of the tumor and identifying tumors with similar genetic alterations and clinical features. Gene expression studies have the ability to recognize distinct subgroups of patients based on similar molecular characteristics and markedly different outcomes that were independent of the International Prognostic Index (IPI). Further, DNA microarray studies also allow identification of new prognostic biomarkers in DLBCL. However, new methods for immunohistochemical analysis of tissue microarray and RNA extraction from paraffin-embedded blocks are required to overcome the major pitfall of this technology-the requirement for fresh tissue. Herein, we summarize the progress made in better prediction of prognosis of DLBCL patients as a result of gene expression profiling.

KW - DLBCL

KW - gene arrays

KW - Prognostic biomarkers

UR - http://www.scopus.com/inward/record.url?scp=37349003104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349003104&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2007.10.020

DO - 10.1016/j.bbmt.2007.10.020

M3 - Article

C2 - 18162230

AN - SCOPUS:37349003104

VL - 14

SP - 108

EP - 111

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 SUPPL.

ER -